ImaginAb launches Japanese subsidiary

Thursday, May 22, 2014

Los Angeles-based ImaginAb, focused on antibody technology for in vivo imaging, has launched ImaginAb Japan. ImaginAb Japan, headquartered in Tokyo, has been established to better meet the commercial needs of several significant clinical development and partnering opportunities for the company. The subsidiary company will be led by Dr. Shintaro Nishimura.

[Read More]

ImaginAb, Lundbeck to collaborate in neurodegeneration

Wednesday, October 10, 2012

ImaginAb, an Inglewood, Calif.-based clinical-stage company developing in vivomolecular imaging agents, has entered into a collaboration and commercialization agreement with Lundbeck, an international pharmaceutical company, on a novel central nervous system (CNS) target in order to explore the use of re-engineered antibodies to accelerate the blood-brain barrier (BBB) transport of biologics.

[Read More]